In an upcoming broadcast, key opinion leaders will discuss clinical efficacy and safety data for a new targeted therapy.
To explore unmet needs for patients with ovarian cancer and obtain expert perspective, watch the live broadcast on 12/14, 6:00pm EST, 12/15, 7:00pm EST and 1/12/23, 8:00pm EST. To register for the event, visit https://studio.mjhassoc.com/reach/National-Broadcast.
US-UNB-2200017 10/22
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
Better Understanding of Biomarkers Can Inform Immunotherapy Treatment in SCLC
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL